SEC Company Response from Black Diamond Therapeutics, (BDTX) — Jan 27, 2020
Black Diamond Therapeutics, Inc.
Date: Jan. 27, 2020 · CIK: 0001701541 · Accession: 0001193125-20-015337
AI Filing Summary & Sentiment
File numbers found in text: 333-235789
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Jefferies LLC
520 Madison Avenue
New York, New York 10022
Cowen and Company, LLC
599 Lexington Avenue
New York, New York 10022
January 27, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549
Attention: Sonia Bednarowski
Dietrich King
Re: Black Diamond Therapeutics, Inc.
Registration Statement on Form S-1, as amended (File No. 333-235789)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Black Diamond Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Daylight Time, on January 29, 2020 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that approximately 1,595 copies of the Preliminary Prospectus, dated January 21, 2020 and included in the above-named Registration Statement, as amended, were distributed during the period from January 21, 2020 through the date hereof, to prospective underwriters, institutions, dealers and others.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
* * *
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 January 27, 2020 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Sonia Bednarowski Dietrich King Re: Black Diamond Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-235789) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Black Diamond Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Daylight Time, on January 29, 2020 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that approximately 1,595 copies of the Preliminary Prospectus, dated January 21, 2020 and included in the above-named Registration Statement, as amended, were distributed during the period from January 21, 2020 through the date hereof, to prospective underwriters, institutions, dealers and others. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. * * * Very truly yours, J.P. MORGAN SECURITIES LLC JEFFERIES LLC COWEN AND COMPANY, LLC Acting on behalf of themselves and the several underwriters By: J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Executive Director By: JEFFERIES LLC By: /s/ Charles L. Glazer Name: Charles L. Glazer Title: Managing Director By: COWEN AND COMPANY, LLC By: /s/ Bill Follis Name: Bill Follis Title: Managing Director [Signature Page to UW Acceleration Request]